Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) shot up 6.1% on Wednesday following insider buying activity. The company traded as high as $5.07 and last traded at $5.07, with a volume of 117,289 shares changing hands. The stock had previously closed at $4.78.
Specifically, major shareholder International S. Pharmstandard acquired 16,977 shares of the firm’s stock in a transaction on Thursday, September 1st. The stock was bought at an average cost of $4.78 per share, with a total value of $81,150.06. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder International S. Pharmstandard acquired 67,371 shares of the firm’s stock in a transaction on Wednesday, August 24th. The shares were bought at an average cost of $4.52 per share, with a total value of $304,516.92. The disclosure for this purchase can be found here. Company insiders own 61.64% of the company’s stock.
Several brokerages have weighed in on ARGS. Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of Argos Therapeutics in a report on Friday, June 17th. Zacks Investment Research raised shares of Argos Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a report on Monday, August 15th. FBR & Co decreased their price objective on shares of Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating for the company in a report on Thursday, August 11th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $11.00 price objective on shares of Argos Therapeutics in a report on Monday, June 20th. Eight equities research analysts have rated the stock with a buy rating, Argos Therapeutics has a consensus rating of “Buy” and an average price target of $11.50.
The company’s 50-day moving average is $4.80 and its 200-day moving average is $5.95. The firm’s market capitalization is $203.51 million.
Argos Therapeutics (NASDAQ:ARGS) last posted its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.05. On average, equities research analysts anticipate that Argos Therapeutics Inc. will post ($1.55) earnings per share for the current fiscal year.
Hedge funds have recently bought and sold shares of the stock. Sanders Morris Harris Inc. acquired a new stake in Argos Therapeutics during the first quarter worth about $907,000. Geode Capital Management LLC boosted its stake in Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 3,559 shares during the period. Bank of New York Mellon Corp boosted its stake in Argos Therapeutics by 184.5% in the second quarter. Bank of New York Mellon Corp now owns 52,215 shares of the biopharmaceutical company’s stock worth $320,000 after buying an additional 33,862 shares during the period. California State Teachers Retirement System acquired a new stake in Argos Therapeutics during the second quarter worth about $137,000. Finally, Oxford Asset Management acquired a new stake in Argos Therapeutics during the second quarter worth about $353,000. Hedge funds and other institutional investors own 11.05% of the company’s stock.
About Argos Therapeutics
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.